학술논문

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
Document Type
Article
Source
In European Journal of Cancer October 2018 102:40-48
Subject
Language
ISSN
0959-8049